Literature DB >> 11867606

Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination.

Tsutomu Yasukawa1, Hideya Kimura, Yasuhiko Tabata, Hiroshi Kamizuru, Hideki Miyamoto, Yoshihito Honda, Yuichiro Ogura.   

Abstract

PURPOSE: Bioactive proteins such as interferon (IFN) have been reported to be combined with water-soluble polymers, such as dextran, through metal coordination, without need for complicated procedures. In the current study, the targeting and inhibitory effects of IFN combined with dextran on experimental choroidal neovascularization (CNV) were studied in vivo.
METHODS: Interferon (IFN)beta was conjugated to dextran, which has metal-chelating, diethylenetriaminepentaacetic acid (DTPA) residues. Based on metal coordination, conjugation of IFNbeta with DTPA-dextran resulted from simply mixing both substances in an aqueous solution containing Zn(2+). The effects of IFNbeta on the proliferation of human umbilical vein endothelial cells (HUVECs) and bovine retinal pigment epithelial cells (BRPECs) were evaluated. To evaluate the activity loss of IFNbeta by conjugation, the effect of the conjugate on HUVECs was compared with that of free IFNbeta. Experimental CNV was induced by subretinal injection of gelatin microspheres containing basic fibroblast growth factor in rabbits. The rabbits with CNV were intravenously treated twice weekly with 7.5 million international units (MIU)/kg per day free IFNbeta (for 4 weeks), with IFNbeta-DTPA-dextran conjugate containing 7.5 (for 2 weeks) or 0.75 (for 4 weeks) MIU/kg per day IFNbeta, or with saline. The effects of these substances were evaluated by fluorescein angiography and histology. To observe the accumulation of conjugate, the doses of IFNbeta in CNV tissues were measured by enzyme-linked immunosorbent assay.
RESULTS: IFNbeta inhibited the growth of HUVECs and enhanced the proliferation of BRPECs. The conjugate seemed to preserve approximately 44% of IFNbeta activity. Although both doses of IFNbeta-DTPA-dextran inhibited progression of CNV in rabbits, longer term administration of a lower dose of IFNbeta-DTPA-dextran had a sustained inhibitory effect on progression of CNV (P < 0.05). Histologic studies revealed the inhibitory effect of IFNbeta-DTPA-dextran on progression of CNV. This conjugate prolonged the plasma half-life of IFNbeta and enabled IFNbeta to accumulate in the CNV in rabbits.
CONCLUSIONS: In this study, human IFNbeta was successfully used to target CNV, an enhanced antiangiogenic effect was achieved by combining it with dextran, based on metal coordination. This targeted delivery of IFNbeta may have potential as a treatment modality for CNV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867606

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Animal models of age-related macular degeneration and their translatability into the clinic.

Authors:  Shida Chen; Nicholas A Popp; Chi-Chao Chan
Journal:  Expert Rev Ophthalmol       Date:  2014-07-12

Review 2.  Biodegradable intraocular therapies for retinal disorders: progress to date.

Authors:  Noriyuki Kuno; Shinobu Fujii
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

3.  Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV.

Authors:  S R Singh; H E Grossniklaus; S J Kang; H F Edelhauser; B K Ambati; U B Kompella
Journal:  Gene Ther       Date:  2009-02-05       Impact factor: 5.250

4.  Immuno-modulatory Effect of IFN-gamma in AMD and its Role as a Possible Target for Therapy.

Authors:  Kailun Jiang; Sijia Cao; Jing Z Cui; Joanne A Matsubara
Journal:  J Clin Exp Ophthalmol       Date:  2013-02-26

5.  Interferon-beta signaling in retinal mononuclear phagocytes attenuates pathological neovascularization.

Authors:  Anika Lückoff; Albert Caramoy; Rebecca Scholz; Marco Prinz; Ulrich Kalinke; Thomas Langmann
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.